APC-2059

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C32H44N10O6
Molecular Weight	664.7552
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12OC[C@@H](OC(=O)N3CCN(CC4=CC=C(NC(N)=N)C=C4)CC3)[C@@]1([H])OC[C@H]2OC(=O)N5CCN(CC6=CC=C(NC(N)=N)C=C6)CC5

InChI

InChIKey=ZHDSRRKNLDCSQJ-BIYDSLDMSA-N

InChI=1S/C32H44N10O6/c33-29(34)37-23-5-1-21(2-6-23)17-39-9-13-41(14-10-39)31(43)47-25-19-45-28-26(20-46-27(25)28)48-32(44)42-15-11-40(12-16-42)18-22-3-7-24(8-4-22)38-30(35)36/h1-8,25-28H,9-20H2,(H4,33,34,37)(H4,35,36,38)/t25-,26-,27-,28-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C32H44N10O6
Molecular Weight	664.7552
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:37:53 GMT 2023` Edited by `admin` on `Fri Dec 15 15:37:53 GMT 2023`
Record UNII	5K2IM57DG0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

APC-2059

Code

English

CRA-2059

Code

English

((3R,3AR,6R,6AR)-6-(4-((4-GUANIDINOPHENYL)METHYLCARBAMOYL)PIPERAZINE-1-CARBONYL)OXY-2,3,3A,5,6,6A-HEXAHYDROFURO(3,2-B)FURAN-3-YL) 4-((4-GUANIDINOPHENYL)METHYLCARBAMOYL)PIPERAZINE-1-CARBOXYLATE

Systematic Name

English

D-MANNITOL, 1,4:3,6-DIANHYDRO-, BIS(4-((4-((AMINOIMINOMETHYL)AMINO)PHENYL)METHYL)-1-PIPERAZINECARBOXYLATE)

Systematic Name

English

Code System Code Type Description

FDA UNII

5K2IM57DG0

Created by admin on Fri Dec 15 15:37:53 GMT 2023 , Edited by admin on Fri Dec 15 15:37:53 GMT 2023

PRIMARY

PUBCHEM

162623533

Created by admin on Fri Dec 15 15:37:53 GMT 2023 , Edited by admin on Fri Dec 15 15:37:53 GMT 2023

PRIMARY

CAS

314777-14-5

Created by admin on Fri Dec 15 15:37:53 GMT 2023 , Edited by admin on Fri Dec 15 15:37:53 GMT 2023

PRIMARY

Related Record Type Details


					5K2IM57DG0

APC-2059

ACTIVE MOIETY

Comments:

The Company also announced that it has successfully completed Phase Ic studies of APC 2059 , an injectable formulation of APC 2059 for the treatment of ulcerative colitis. This trial showed that, at the planned Phase II dose administered by subcutaneous injection, the drug is well tolerated and produces the desired blood concentrations in normal volunteers.